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ABSTRACT

The presently-disclosed subject matter relates to RNA-based
composition and method to treat gastric cancer in a subject.
More particularly, the presently disclosed subject matter
relates to a RNA nanostructure and composition containing
a multiple branched RNA nanoparticle, a gastric cancer
targeting module, and an effective amount of a therapeutic
agent. Further, the presently disclosed subject matter relates
to a method of using the RNA nanoparticle composition to
treat gastric cancer in a subject having or at risk of having
gastric cancer.
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RNA NANOPARTICLE FOR TREATMENT OF
GASTRIC CANCER

dots (13), folic acid conjugated upper conversion nanoparticles (14), Folate conjugated gold nanorods (15), ce6conjugated carbon dots (16), ce6-conjugated Au nanoclusters (Au NCs) (17,18). However, clinical translation of these
prepared nanoprobes still presents great challenge because
all these prepared nanoprobes are not only distributed to the
site of gastric cancer, but also partially accumulated in other
organs. Therefore, the development of safe and effective
nanoprobes for in vivo targeted delivery, imaging and simultaneous therapy of early gastric cancer is desirable.

RELATED APPLICATIONS
5

This application is a § 371 National State Application of
PCT/US2016/021444 filed Mar. 9, 2016 which claims the
benefit of U.S. Provisional Patent Application No. 62/130,
527, filed Mar. 9, 2015, the entire disclosure of which are
hereby incorporated by reference in their entirety.
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SUMMARY

GOVERNMENT INTEREST
This invention was made with govermnent support under
CA151648 and EB012135 awarded by the National Institutes of Health. The government has certain rights in the
invention.
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SEQUENCE LISTING
20

The instant application contains a Sequence Listing which
has been submitted electronically in ASCII format and is
hereby incorporated by reference in its entirety. Said ASCII
copy, created on Dec. 20, 2017, is named 2935720-006-US2
SL.txt and is 5,228 bytes in size.
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TECHNICAL FIELD
The presently-disclosed subject matter relates to RNA
nano structure molecule and method to treat gastric cancer in
a subject. More particularly, the presently disclosed subject
matter relates to a RNA nanostructure and composition
containing a multiple branched RNA nanoparticle, a gastric
cancer targeting module, and an effective amount of a
therapeutic agent. Further, the presently disclosed subject
matter relates to a method of using the RNA nanoparticle
composition to treat gastric cancer in a subject having or at
risk of having gastric cancer.
INTRODUCTION
Gastric cancer is the one of the most common cancers,
and the second leading cause of cancer-related death in the
world (1,2). The effective treatment remains challenging
primarily because most diagnosed patients present advanced
stages of the disease. It remains very difficult to cure
effectively, primarily because most patients present
advanced stages of the diseases. Up to date, surgery, radiation and chemotherapies are generally very effective for
early and in situ gastric cancers, but advanced and metastatic
cases do not respond to chemo- or radiation therapies (3-5)
and resistance to chemotherapy-induced apoptosis is a major
cause for the failure of conventional therapies (6-8). The
current prognosis of gastric cancer is very poor with 5-year
survivals of less than 24% (9). Therefore, developing novel
strategies and approaches for recognizing, tracking and
killing gastric cancer cells in early disease stage is urgently
demand.
Previously, multifunctional nanoprobes has been studies
to realize targeted imaging and simultaneous therapy of
gastric cancer (10,11). The previous studies show that subcutaneous and in situ gastric cancer tissues with 5 mm in
diameter could be recognized and treated using multifunctional nanoprobes such as BRCAAl (breast cancer associated antigen 1, AF208045) monoclonal antibody-conjugated
fluorescent magnetic nanoparticles (12), Her2 monoclonal
antibody-conjugated RNase-A-associated CdTe quantum
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The presently-disclosed subject matter meets some or all
of the above-identified needs, as will become evident to
those of ordinary skill in the art after a study of information
provided in this document.
This Summary describes several embodiments of the
presently-disclosed subject matter, and in many cases lists
variations and permutations of these embodiments. This
Summary is merely exemplary of the numerous and varied
embodiments. Mention of one or more representative features of a given embodiment is likewise exemplary. Such an
embodiment can typically exist with or without the
feature(s) mentioned; likewise, those features can be applied
to other embodiments of the presently-disclosed subject
matter, whether listed in this Summary or not. To avoid
excessive repetition, this Summary does not list or suggest
all possible combinations of such features.
The presently disclosed subject matter in some embodiments relates to an artificial RNA nanostructure molecule.
The RNA nanostructure molecule includes a multiple
branched RNA junction motif comprising at least one RNA
oligonucleotides, and a gastric cancer targeting module
conjugated to the RNA junction motif. In some embodiments, the RNA nanostructure further includes at least one
bioactive agent. In some embodiments, the RNA nano structure binds to gastric cancer cells. A non-limiting example of
the bioactive agent is a therapeutic agent. In some embodiments, the bioactive agent includes drugs, fluorescent dyes,
or chemicals. In some embodiments, the bioactive agent
includes an imaging module. Non-limiting examples of the
imaging module is fluorescent dye, including a non-limiting
example Alexa647. In some embodiments, the diameter of
the molecule is at least about 40 nm or less. In some
embodiments, the molecule has zeta potential ranging from
about -150 m V to about 150 m V. In some embodiments, the
molecule has zeta potential ranging from about -125 my to
about 75 mV. In some embodiments, the molecule is substantially stable in a pH value ranges from about 2 to about
13.
In some embodiments, the nanostructure comprises at
least one chemical modification at 2' position. Non-limiting
examples of the chemical modification includes 2'Fluoro,
2'Amine, and 2'O-Methyl. In some embodiments, the multiple branched RNA comprises sequence 5'-CCACAUAAAGGGCCCACUAuuCCCACAUACUUUGUUGAUCC-3' (SEQ ID NO: 4). In some embodiments,
the multiple branched RNA includes sequence
5'-UAGUGGGCCCUUUAUGUGG-3' (SEQ ID NO: 5).
In some embodiments, the multiple branched RNA junction motif is a three-branched RNA junction motif. In some
embodiments of the present disclosure, the RNA molecules
form dimers, trimers, hexamers, and patterned superstructures. Further, In some embodiments, a branch of the threebranched RNA junction motif includes an a3WJ RNA
module (SEQ ID NO: 1); a b3WJ RNA module (SEQ ID

US 10,781,446 B2
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NO: 2); or a c3WJ RNA module (SEQ ID NO: 3). In one
embodiment, the three-branched RNA junction motif comprises an a3WJ RNA module (SEQ ID NO: 1); a b3WJ RNA
module (SEQ ID NO: 2); and a c3WJ RNA module (SEQ ID
NO: 3). The SEQ ID NO: 1 includes nucleotide sequence
5'-UUG CCA UGU GUA UGU GGG-3', the SEQ ID NO: 2
comprises nucleotide sequence 5'-CCC ACA UAC UUU
GUU GAUCC-3', and the SEQ ID NO: 3 comprises nucleotide sequence 5'-GGA UCAAUC AUG GCAA-3'.
In some embodiments, the gastric cancer targeting module includes a ligand that binds to at least one gastric cancer
cell surface marker. In some embodiments, the ligand binds
to a folate receptor, an epidermal growth factor receptor 2
(ErbB-2/HER2), an epidermal growth factor receptor
(EGFR), a HER2 or a combination thereof. In some embodiments, the ligand is an aptamer. Non-limiting examples of
the aptamer are aptamers binding to EGFR, PDGFR, folate
receptor, or a combination thereof. In one example, the
ligand is a EGFR targeting aptamer. In one example, the
ligand has sequence 5'-G CCU UAG UAA CGU GCU UUG
AUG UCG AUU CGA CAG GAG GC 3' (SEQ ID NO: 6).
In some embodiments, the targeting module is a folate.
Non-limiting examples of folate are folic acid, 5-methyltetrahydro folate, 5-formyltetrahydrofolate, dihydrofolate, tetrahydrofolate, or a combination thereof.
In some embodiments, the bioactive agent is a drug, a
fluorescent dye, a chemical, or a combination thereof. In
some embodiments, wherein the bioactive agent is a siRNA,
a miRNA, an anti-mRNA, a ribozyme RNAs, or an antisense
RNAs. In some embodiments, the bioactive agent is directed
a gastric cancer marker. In some embodiments, the bioactive
agent is a siRNA sequence. Non-limiting examples of the
siRNA are siRNA is directed to Survivin, Bcl-2, XIAP,
BCL-XL, or BRCAAl. Non-limiting examples of the
siRNA include siRNA sequence 5' GGACCACCGCAUCUCUACAdTdT 3' (SEQ ID NO: 7), 5' dTdTCCUGGUGGCGUAGAGAUGU 3' (SEQ ID NO: 8), 5'-AAGCUGuCACAGAGGGGCUAC-3'
(SEQ
ID
NO:
9),
5'GUAGCCCCUCUGUGACAGCUU-3 (SEQ ID NO: 10),
5'-CCAUGUGCUAUACAGUCAUUACUUU-3' (SEQ ID
NO: 11 ), 5'-AAAGUAAUGACUGUAUAGCACAUGG-3'
(SEQ ID NO: 12), 5'-UUGGACAAUGGACUGGUUGA-3'
(SEQ ID NO: 13), or 5'-UCAACCAGUCCAUUGUCCAA-3 (SEQ ID NO: 14). In one embodiment, siRNA is a
BRCAAl siRNA. A non-limiting example is a siRNA
sequence 5'-CCACAUAAAGGGCCCACUA-3' (SEQ ID
NO: 15). Another non-limiting example is a siRNA
sequence 5'-UAGUGGGCCCUUUAUGUGG-3' (SEQ ID
NO: 5). In some embodiments, the bioactive agent is a
microRNA sequence. In some embodiments, the bioactive
agent is an anti-miRNA molecule for a miRNA comprising
miR-9, miR-l0b, miR-21, or miR-26. In some embodiments, the bioactive agent is a miRNA molecule for a
miRNA comprising let-7a, miR-l0b, miR-25, miR-34a,
miR-124, miR-145, or miR-181b.
Further provided, in some embodiments of the presently
disclosed subject matter, is a composition including a therapeutically effective amount of the RNA nano structure molecule as disclosed above and herein. In some embodiments,
the composition further includes a pharmaceutically acceptable carrier.
Still further, the presently disclosed subject matter in
some embodiments provides a nanoparticle delivery system
including a RNA nano structure molecule as disclosed above
and herein. In some embodiments, the delivery system
further includes a pharmaceutically acceptable carrier.

Yet further provided in some embodiments, is a method of
treating gastric cancer in a subject having or at risk of having
gastric cancer. The method includes the step of administering to the subject a therapeutically effective amount of a
composition comprising the RNA nano structure molecule as
disclosed above and herein. In some embodiments, the
method includes a composition further including a pharmaceutically acceptable carrier. In some embodiments, the
subject is a mammal or a non-mammal vertebrate. In some
embodiments, the subject is a human.
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FIGS. lA and 1B include diagrams and images illustrating the global structure of the therapeutic RNA nanoparticles
with BRCAAl siRNA. FIG. lA is the design of the RNA
nanoparticles (SEQ ID NOS 1, 16, 3 and 4, respectively, in
order of appearance). Left is the one use in animal trial.
Right is the extended one to prepare the AFM images. FIG.
1B is the AFM image of extended 3WJ RNA nanoparticles.
The RNA complex in left of a is estimated to be around 10
nm. Due to convolution of the tip size HO nm in diameter)
in AFM images, features smaller than the size of the tip
carmot be resolved. To characterize the structure of the RNA
constructs, the 3WJ nanoparticles were extended by 39-60
base-pairs (in red color), which is within the persistence
length of dsRNA and will not affect the 3WJ folding as
described before (31 ), to generate the AFM image as shown.
FIG. 2 includes graphs showing flow cytometry analysis
for specific binding of 3WJ-FA-A647 nanoparticles to
MGC803 cells (left, folate positive), GES-1 cells (right,
folate negative control).
FIG. 3 shows the BRCAAl silencing effects of
FA-pRNA-3WJ-BRCAAlsiRNA assayed by (a) qRT-PCR
(GAD PH is the endogenous control) (there existed statistical
difference between FA-pRNA-3WJ-BRCAAlsiRNA group
and FA-pRNA-3WJ-Scramb-siRNA group, P<0.01) and (b)
western blot assay (~-actin bands served as loading control).
FIG. 4 is a graph showing inhibition of the growth of
MGC803 cells by the nanoparticle of FA-pRNA-3WJBRCAAlsiRNA using CCK8 (Cell Counting Kit-8) assays.
The "Control" is non-treated MGC803 cells.
FIG. 5 includes graphs showing determination of cell
death by flow cytometry of Annexin V-FITC/PI staining in
MGC803 cells transfected with 25 nM FA-pRNA-3WJBRCAAlsiRNA or FA-pRNA-3WJ-Scram-siRNA for 48 h.
FIG. 6A includes images showing representative in vivo
fluorescence images of MGC803-tumour-bearing mouse
after iv-injected with FA-AlexaFluor647-labeled pRNA
nanoparticle. The tumor areas are indicated with arrows.
FIG. 6B shows representative ex vivo images of tumors and
organs. Labels: 1, tumor; 2, heart; 3, liver; 4, spleen; 5, lung;
6, Stomach; 7, kidneys; 8, bladder; 9, muscle. FIG. 6C is a
graphs showing the average fluorescence intensities from the
tumor areas of post-injection (3 mice per time point). The
error bars represent SEM (n=3).
FIG. 7 includes images showing tumor sizes in test group
and control group under different days FIG. 7A is an image
showing 0 day at un-treated mouse; FIG. 7B is an image
showing Oday in un-treated mouse; FIG. 7C shows 14 days
at control mouse; FIG. 7D is an image showing 14 days in
test mouse, and FIG. 7E shows tumor tissues from experiment.
FIG. 8 is a graph showing the tumor size curve as the
post-treatment time increases. There existed statistical dif-

US 10,781,446 B2
5

6

ference between FA-pRNA-3WJ-BRCAAlsiRNA treated
group and FA-pRNA-3WJ-Scram-siRNA treated group,
P<0.01.
FIG. 9 includes images showing the result of HE immunostaining of important organs showing the undetectable
damage.
FIG. 10 is an images showing the expression of related
apoptosis proteins of MGC803 cells at 48 h post-treatment
by Western blotting. 1: scrambled control; 2: FA-AlexaFluor647-labeled pRNA nanoparticle; 3: control.
FIG. 11 is a diagram showing the potential mechanism of
RNA nanoparticles for gastric cancer therapy.
FIG. 12A is an graph showing the size of 3WJ-BRCAA1
siRNA nanoparticle. FIG. 12B is a graph showing the zeta
potential of 3WJ-BRCAA1 siRNA nanoparticle. The RNA
nanoparticles were dissolved in 1xTMS buffer with concentration at 1.5 µM and then were measured by Zetasizer
nano-ZS (Malvern Instrument). The data showed that the
size of the nanoparticle is 5.20±0.83 nm in diameter, and the
zeta potential is -16.57±0.75 my, as shown in Figure SIA
and SIB. The data were obtained from three independent
measurements.
FIG. 13 includes a graph and an image showing the effects
of pH on the fluorescent intensity and stability of RNA
nanoparticles. FIG. 13A is a graphs illustrating the effects of
pH (pH 2 to 13) on the fluorescent intensity of RNA
nanoparticles by PerkinElmer LS 55 spectrofluorimeter, and
FIG. 13B is an image showing the effects of pH (pH 2 to 13)
on the stability of RNA nanoparticles examined by 1.2%
agarose gel electrophoresis.
FIG. 14 is a graphs showing the determination of the
melting temperature of the 3WJ-BRCAA1 siRNA nanoparticle.
FIG. 15 is an image showing the effects of RNAase A on
the stability ofRNAnanoparticles. Lane 1: 10 U RNAaseA;
Lane2: 50 U RNAaseA, Lane 3: 100 U RNAaseA, Lane 4:
500 U RNAase A; Lane 5: 1000 U RNAase A; Lane 6:
10000 U RNAase A. RNA nanoparticles on different lanes
exhibited identical position, similar brightness and no obvious degradation, suggesting that prepared RNA nanoparticles have good stability against RNase A (less than 10000
U)-mediated degradation.
FIG. 16 is a graph showing light scattering plots of
MGC803 cells at 48 h treated with FA-pRNA-3WJ-BRCAAl-siRNA nanoparticles.

such publicly-available databases are references to the most
recent version of the database as of the filing date of this
Application.
While the terms used herein are believed to be well
understood by one of ordinary skill in the art, definitions are
set forth to facilitate explanation of the presently-disclosed
subject matter.
Unless defined otherwise, all technical and scientific
terms used herein have the same meaning as commonly
understood by one of ordinary skill in the art to which the
presently-disclosed subject matter belongs. Although any
methods, devices, and materials similar or equivalent to
those described herein can be used in the practice or testing
of the presently-disclosed subject matter, representative
methods, devices, and materials are now described.
Following long-standing patent law convention, the terms
"a", "an", and "the" refer to "one or more" when used in this
application, including the claims. Thus, for example, reference to "a cell" includes a plurality of such cells, and so
forth.
Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as reaction conditions,
and so forth used in the specification and claims are to be
understood as being modified in all instances by the term
"about". Accordingly, unless indicated to the contrary, the
numerical parameters set forth in this specification and
claims are approximations that can vary depending upon the
desired properties sought to be obtained by the presentlydisclosed subject matter.
As used herein, the term "about," when referring to a
value or to an amount of mass, weight, time, volume,
concentration or percentage is meant to encompass variations of in some embodiments ±20%, in some embodiments
±10%, in some embodiments ±5%, in some embodiments
±1 %, in some embodiments ±0.5%, and in some embodiments ±0.1 % from the specified amount, as such variations
are appropriate to perform the disclosed method. As used
herein, ranges can be expressed as from "about" one particular value, and/or to "about" another particular value. It is
also understood that there are a number of values disclosed
herein, and that each value is also herein disclosed as
"about" that particular value in addition to the value itself.
For example, if the value "10" is disclosed, then "about 10"
is also disclosed. It is also understood that each unit between
two particular units are also disclosed. For example, if 10
and 15 are disclosed, then 11, 12, 13, and 14 are also
disclosed.
The presently disclosed subject matter in some embodiments relates to an artificial RNA nanostructure molecule.
The RNA nanostructure molecule includes a multiple
branched RNA junction motif comprising at least one RNA
oligonucleotides, and a gastric cancer targeting module
conjugated to the RNA junction motif. In some embodiments, the RNA oligonucleotides is at least 6 nucleotides in
length. In some embodiments, the RNA nanostructure further includes at least one bioactive agent. In some embodiments, the RNA nanostructure binds to gastric cancer cells.
A non-limiting example of the bioactive agent is a therapeutic agent. In some embodiments, the bioactive agent
includes drugs, fluorescent dyes, or chemicals. In some
embodiments, the bioactive agent includes an imaging module. Non-limiting examples of the imaging module is fluorescent dye, including a non-limiting example Alexa647. In
some embodiments, the nanostructure comprises at least one
chemical modification at 2' position. Non-limiting examples
of the chemical modification includes 2'Fluoro, 2'Amine,
and 2'O-Methyl. In some embodiments, the multiple
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The details of one or more embodiments of the presentlydisclosed subject matter are set forth in this document.
Modifications to embodiments described in this document,
and other embodiments, will be evident to those of ordinary
skill in the art after a study of the information provided in
this document. The information provided in this document,
and particularly the specific details of the described exemplary embodiments, is provided primarily for clearness of
understanding and no unnecessary limitations are to be
understood therefrom.
In certain instances, nucleotides and polypeptides disclosed herein are included in publicly-available databases,
such as GENBANK® and SWISSPROT. Information
including sequences and other information related to such
nucleotides and polypeptides included in such publiclyavailable databases are expressly incorporated by reference.
Unless otherwise indicated or apparent the references to
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branched
RNA
comprises
sequence
5'-CCACAUAAAGGGCCCACUAuuCCCACAUACUUUGUUGAUCC-3' (SEQ ID NO: 4). In some embodiments,
the multiple branched RNA includes sequence
5'-UAGUGGGCCCUUUAUGUGG-3' (SEQ ID NO: 5).
The term "RNA" refers to a molecule comprising at least
one ribonucleotide residue. By "ribonucleotide" is meant a
nucleotide with a hydroxyl group at the 2' position of a
~-D-ribofuranose moiety. The terms encompass double
stranded RNA, single stranded RNA, RNAs with both
double stranded and single stranded regions, isolated RNA
such as partially purified RNA, essentially pure RNA,
synthetic RNA, recombinantly produced RNA, as well as
altered RNA, or analog RNA, that differs from naturally
occurring RNA by the addition, deletion, substitution, and/or
alteration of one or more nucleotides. Such alterations can
include addition of non-nucleotide material, such as to the
end( s) of an siRNA or internally, for example at one or more
nucleotides of the RNA. Nucleotides in the RNA molecules
of the presently disclosed subject matter can also comprise
non-standard nucleotides, such as non-naturally occurring
nucleotides or chemically synthesized nucleotides or deoxynucleotides. These altered RNAs can be referred to as
analogs or analogs of a naturally occurring RNA.
As disclosed herein, RNA nanotechnology has recently
emerged as an important field due to recent finding of its
high thermodynamic stability, favorable and distinctive in
vivo attributes (US 2014/0179758, hereby incorporate by
reference in its entirety). In some embodiments of the
present disclosure, as disclosed in US2014/0179758, the
RNA molecules form dimers, trimers, hexamers, and patterned superstructures. Further, RNA nanoparticles can be
fabricated with precise control of shape, size and stoichiometry, as demonstrated by the packaging RNA (pRNA) of
the bacteriophage phi29 DNA packaging motor, which
forms dimmers, trimers, and hexamers via hand-in-hand
interactions of the interlocking loops (27,28). The pRNA
contains an ultra-stable three-way junction (3WJ) motif
(29-31 ), which can be assembled from three short fragments
with extremely high affinity. Recently, the crystal structure
of the pRNA-3WJ motif was obtained (32) and a variety of
therapeutic RNA nanoparticles using the pRNA-3WJ and
pRNA-X motifs as scaffolds have been constructed (33-34).
The pRNA-3WJ nanoparticles display thermodynamically
stable properties, including high melting temperature with
low free energy, resistance to denaturation in SM urea, and
resistance to dissociation at very low concentrations in the
blood. Boiling resistant RNA nanoparticles with controllable
shapes and defined stoichiometry have recently been
reported (36). Various imaging groups, such as fluorophores;
targeting ligands, such as receptor binding aptamers; and
therapeutic modules, such as siRNA, miRNA or ribozymes
can be integrated into the 3WJ scaffold without affecting the
folding and functionality of the core motif and incorporated
functional moieties. Upon 2'-Fluoro (2'-F) modifications of
Uracil (U) and Cytosine (C) nucleotides, the RNA nanoparticles become resistant to RNase degradation with enhanced
in vivo half-life while retaining authentic functions of the
incorporated modules. Furthermore, the pRNA nanoparticles are non-toxic, non-immunogenic, and display favorable biodistribution and pharmacokinetic profiles in mice.
In some embodiments, the multiple branched RNA junction motif is a three-branched RNA junction motif. In some
embodiments of the present disclosure, the RNA molecules
form dimers, trimers, hexamers, and patterned superstructures. Further, In some embodiments, a branch of the threebranched RNA junction motif includes an a3WJ RNA

module (SEQ ID NO: 1); a b3WJ RNA module (SEQ ID
NO: 2); or a c3WJ RNA module (SEQ ID NO: 3). In one
embodiment, the three-branched RNA junction motif comprises an a3WJ RNA module (SEQ ID NO: 1); a b3WJ RNA
module (SEQ ID NO: 2); and a c3WJ RNA module (SEQ ID
NO: 3). The SEQ ID NO: 1 includes nucleotide sequence
5'-UUG CCA UGU GUA UGU GGG-3', the SEQ ID NO: 2
comprises nucleotide sequence 5'-CCC ACA UAC UUU
GUU GAUCC-3', and the SEQ ID NO: 3 comprises nucleotide sequence 5'-GGA UCA AUC AUG GCA A-3'.
In some embodiments, the diameter of the molecule is at
least about 40 nm or less. The diameter is at least about 35
nm or less, at least about 30 nm or less, at least about 25 nm
or less, at least 20 nm or less, at least 15 nm or less, at least
10 nm or less, at least 5 nm or less.
In some embodiments, the molecule has zeta potential
ranging from about -150 mV to about 150 mV. The RNA
molecule has a zeta potential ranging from about -140 mV
to about 140 mV, from about -130 mV to about 130 mV,
from about -120 m V to about 120 m V, from about -110 m V
to about 110 m V, from about -100 m V to about 100 m V,
from about -90 to about 90 m V, form about -80 m V to about
80 m V, from about - 70 m V to about 70 m V, from about -60
m V to about 60 m V, from about -50 m V to about 50 m V.
The molecule has a zeta potential ranging from about -40
my to about 40 mV, from about -30 mV to about 30 mV,
from about -20 m V to about 20 m V, from about -10 m V to
about 10 mV.
In some embodiments, the molecule is substantially stable
in a pH value ranges from about 2 to about 13. The RNA
molecule is substantially stable in pH about 2, 3, 4, 5, 6, 7,
8, 9, 10, 11, 12 and 13. As used herein, the term "substantially stable" can refer to physical and/or chemical stability.
As will be recognized by those of ordinary skill in the art,
the term "substantially stable" can refer to stability of the
composition under certain conditions, relative to an initial
composition (i.e., when a particular batch of the composition
is initially prepared). In this regard, as will be recognized by
those of ordinary skill in the art, one manner in which
stability of a particular embodiment of the composition can
be determined is as follows: preparing a batch of the
embodiment of the composition, making an initial assessment of a sample of the composition (control sample),
subjecting a sample of the composition to conditions of
interest (e.g., storage at a particular temperature for a
particular time period) (test sample), making an assessment
of the test sample, and comparing the assessment of the
control sample to the assessment of the test sample. Calculations can be made to determine whether the amounts
present in the test sample are 100%±20, 19, 18, 17, 16, 15,
14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, 0.5, or 0.1 % of the
amount that is in the control sample.
In some embodiments, the RNA nanostructure includes a
gastric cancer targeting module. In some embodiments, the
gastric cancer targeting module includes a ligand that binds
to at least one gastric cancer cell surface marker. In some
embodiments, the ligand binds to a folate receptor, an
epidermal growth factor receptor 2 (ErbB-2/HER2), an
epidermal growth factor receptor (EGFR), a HER2 or a
combination thereof. In some embodiments, the ligand is an
aptamer. The term "aptamer" as used herein refers to an
oligonucleotide that can bind specifically to its target with
high affinity. Non-limiting examples of the aptamer are
aptamers binding to EGFR, PDGFR, folate receptor, or a
combination thereof. In one example, the ligand is a EGFR
targeting aptamer. In one example, the ligand has sequence
5'-G CCU UAG UAA CGU GCU UUG AUG UCG AUU
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CGA CAG GAG GC 3' (SEQ ID NO: 6). In some embodiments, the targeting module is a folate.
The term "folate" as used herein can comprise a genus of
well-defined B-vitamin compounds, including but not limited to, 5-methyltetrahydro folate, 5-formyltetrahydrofolate,
dihydrofolate, tetrahydrofolate, folic acid and other folate
compounds. As disclosed herein, the targeted delivery systems call for a ligand-receptor pair that is specifically found
in cancer cells. Many, but not all, cancer cells, including
stomach, ovary, lung, breast, kidney, endometrium, colon
and hematopoietic cells, over-expressed folate receptors
(FRs) than normal cells for high uptake of folate, since folate
is essential component during DNA replication and methylation in highly proliferating cells. Folic acid (FA), a
synthetic oxidized form offolate, has been widely used as a
ligand conjugate in various cancer targeting materials.
In some embodiments, the bioactive agent is a drug, a
fluorescent dye, a chemical, or a combination thereof. In
some embodiments, wherein the bioactive agent is a siRNA,
a miRNA, an anti-mRNA, a ribozyme RNAs, or an antisense
RNAs. In some embodiments, the bioactive agent is directed
a gastric cancer marker. In some embodiments, the bioactive
agent is a siRNA sequence. Non-limiting examples of the
siRNA are siRNA is directed to Survivin, Bcl-2, XIAP,
BCL-XL, or BRCAAl.
In some embodiments of the present disclosure, a RNA
nanotechnology approach is adopted to overcome some of
the aforementioned challenges, and report the strategy to
target and deliver therapeutic BRCAAl siRNA to in vivo
stomach cancer tissues using FA-conjugated pRNA-3WJ
nanoparticles. The present disclosure relates to the construction of multi-functional, thermodynamically and chemically
stable RNA nanoparticles harboring sequences that allow
specific binding to stomach cancer specific cell surface
antigens or receptors resulting in the internalization of RNA
nanoparticles into target cells and delivery of the siRNA,
miRNA, and drugs for attaining synergistic effects for the
treatment of stomach cancer. Further, the present disclosure
relates to effects of prepared RNA nanoparticles on the
regression of gastric cancer tissues in vivo, and potential
molecular mechanism.
It has been proposed for long time that the RNAi can be
applied for potential cancer treatment strategy. However,
lacking of effect delivery system, the therapeutic small
RNAs including siRNAs, miRNAs, anti-sense RNAs, etc.,
remain undrugable. The RNA nanoparticle-based nano-delivery platform can overcome aforementioned limitations
for conventional cancer therapeutic and opens new opportunities for specific delivering RNAi therapeutics to gastric
cancer without damaging healthy organs and tissues, reducing the toxicity and side effects, improving the therapeutic
effects, and exhibiting great potential in clinical cancer
therapy.
The phrase "gastric cancer marker" as used herein refers
to genes or gene products (e.g., RNA molecules or proteins)
which are characteristic of some or all of the cells in gastric
cancer. A gastric cancer marker with diagnostic value can be
a gene or gene product expressed in normal, non-cancerous
cells, but is characteristic of a type or classification of cancer
by, for example, its over-expression or under-expression as
compared to its expression in normal, non-cancerous cells.
A gastric cancer marker with prognostic value is a gene or
gene product for which the over-expression or under-expression confers predictive information about the future
aggressiveness of a cancer and/or its response to therapy at
the time of diagnosis. In a cancer sample, the patterns of
expression of diagnostic and prognostic cancer markers

allow one to accurately identify and determine the future
course of the disease, respectively. Non-limiting examples
of gastric cancer biomarkers are described in
WO2012167112 (herein incorporated by reference in its
entirety).
The terms "small interfering RNA", "short interfering
RNA", "small hairpin RNA", "siRNA", and shRNA are
used interchangeably and refer to any nucleic acid molecule
capable of mediating RNA interference (RNAi) or gene
silencing. See e.g., Bass, Nature 411 :428-429, 2001;
Elbashir et al., Nature 411 :494-498, 2001a; and PCT International Publication Nos. WO 00/44895, WO 01/36646,
WO 99/32619, WO 00/01846, WO 01/29058, WO
99/07409, and WO 00/44914. In one embodiment, the
siRNA comprises a double stranded polynucleotide molecule comprising complementary sense and antisense
regions, wherein the antisense region comprises a sequence
complementary to a region of a target nucleic acid molecule
(for example, a nucleic acid molecule encoding Survivin). In
another embodiment, the siRNA comprises a single stranded
polynucleotide having self-complementary sense and antisense regions, wherein the antisense region comprises a
sequence complementary to a region of a target nucleic acid
molecule. In another embodiment, the siRNA comprises a
single stranded polynucleotide having one or more loop
structures and a stem comprising self complementary sense
and antisense regions, wherein the antisense region comprises a sequence complementary to a region of a target
nucleic acid molecule, and wherein the polynucleotide can
be processed either in vivo or in vitro to generate an active
siRNA capable of mediating RNAi. As used herein, siRNA
molecules need not be limited to those molecules containing
only RNA, but further encompass chemically modified
nucleotides and non-nucleotides.
In some embodiments, the presently disclosed subject
matter takes advantage of the ability of short, double
stranded RNA molecules to cause the down regulation of
cellular genes, a process referred to as RNA interference. As
used herein, "RNA interference" (RNAi) refers to a process
of sequence-specific post-transcriptional gene silencing
mediated by a small interfering RNA (siRNA). See Fire et
al., Nature 391:806-811, 1998 and U.S. Pat. No. 6,506,559,
each of which is incorporated by reference herein in its
entirety. The process of post-transcriptional gene silencing is
thought to be an evolutionarily conserved cellular defense
mechanism that has evolved to prevent the expression of
foreign genes (Fire, Trends Genet 15:358-363, 1999).
Disclosed herein are examples of siRNA including Survivin-specific, Bcl-2, XIAP, and BCL-XL siRNA sequences.
The Survivin-specific siRNA includes sense sequence: 5'
GGACCACCGCAUCUCUACAdTdT 3' (SEQ ID NO: 7)
and antisense sequence: 5' dTdTCCUGGUGGCGUAGAGAUGU 3' (SEQ ID NO: 8) (See, e.g., Cancer Gene Ther.
2004 March; 11(3):186-93. Knockdown of survivin expression by small interfering RNA reduces the clonogenic survival of human sarcoma cell lines independently of p53.);
the Bcl-2 siRNA includes sense sequence: 5'-AAGCUGuCACAGAGGGGCUAC-3' (SEQ ID NO: 9), and antisense
sequence: 5'-GUAGCCCCUCUGUGACAGCUU-3 (SEQ
ID NO: 10) (See, e.g., Nucleic Acids Res. 2012 July;
40(13):6319-37. doi: 10.1093/nar/gks294. Epub 2012 Mar.
30. Delivery of chemo-sensitizing siRNAs to HER2+-breast
cancer cells using RNA aptamers.); XIAP siRNA includes
sense sequence: 5'-CCAUGUGCUAUACAGUCAUUACUUU-3 (SEQ ID NO: 11), and antisense sequence:
5'-AAAGUAAUGACUGUAUAGCACAUGG-3 (SEQ ID
NO: 12) (See, e.g., Mal Cancer. 2006 Sep. 5; 5:34. Specific
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down-regulation of XIAP with RNA interference enhances
the sensitivity of canine tumor cell-lines to TRAIL and
doxorubicin); and BCL-XL siRNA includes sense sequence:
5'-UUGGACAAUGGACUGGUUGA-3 (SEQ ID NO: 13),
antisense sequence: 5'-UCAACCAGUCCAUUGUCCAA-3
(SEQ ID NO: 14) (See, e.g., Acta Biochim Biophys Sin
(Shanghai). 2005 August; 37(8):555-60. Silencing of BelXL expression in human MGC-803 gastric cancer cells by
siRNA.) Further, in one embodiment, siRNA is a BRCAAl
siRNA. A non-limiting example is a siRNA sequence
5'-CCACAUAAAGGGCCCACUA-3' (SEQ ID NO: 15).
Another non-limiting example is a siRNA sequence
5'-UAGUGGGCCCUUUAUGUGG-3' (SEQ ID NO: 5).
In some embodiments, the bioactive agent is a microRNA
sequence. The term "Micro RNAs (miRNAs )" as used herein
are single-stranded, or double stranded non-coding RNAs, at
least about 6 nucleotide in length that can regulate gene
expression at the post-transcriptional level by either degrading their target mRNAs or inhibiting their translation (1,2).
MiRNAs play important roles in regulating cell cycle,
proliferation, differentiation, metabolism, and apoptosis (1).
A compendium of microRNA and respective microRNA
binding sequences is available at the miRNA registry. (See,
e.g., Griffiths-Jones et al. (2006) Nucl. Acids Res. 34:D140D144; US20140045709, herein incorporate by reference in
their entireties.) In particular embodiments, the microRNA
and microRNA binding sequence employed in the present
assay are associated with a disease or condition, wherein an
antagonist or agonist to the microRNA would be useful in
preventing or treating the disease or condition.
In some embodiments, the present disclosure provides
inhibitors of miRNAs (e.g., anti-miR-21). Compositions
comprising such inhibitors and methods for inhibiting miR21 using such inhibitors are also disclosed herein. Any
miRNA inhibitor may be used alone, or with other miRNA
inhibitor(s) known in the art. In some embodiments, the
miRNA inhibitor comprises an antisense molecule. In some
embodiments, the antisense molecule could be a single or a
double stranded sequence. Examples of antisense molecule
include, but are not limited to, siRNAs, triple-helix-forming
agents, ribozymes, RNAi, synthetic peptide nucleic acids
(PNAs), antigenes (agRNAs), LNA/DNAcopolymers, small
molecule chemical compounds, and antisense oligonucleotides.
In some embodiments, the microRNA sequence is at least
6 nucleotide in length. In some embodiments, the miRNA
molecule or an equivalent, or a mimic thereof is from about
6 to about 30 nucleotides in length. In some embodiments,
the miRNA is about 12 to about 30 nucleotides in length. In
some embodiments, the miRNA is from about 15 to about 28
nucleotides in length. In some embodiments, the miRNA is
about 19 to about 25 nucleotides in length. In some embodiments, the miRNA molecule has a length of at least about 6,
7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23,
24, 25, 26, 27, 28, 29, about 30 nucleotides or more. In some
embodiments, an antagomir of a miRNA molecule is from
about 6 to about 30 nucleotides in length, from about 10 to
about 30 nucleotides in length, from about 12 to about 28
nucleotides in length. In some embodiments, the antagomir
of a miRNA molecule has a length of at least about 6, 7, 8,
9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,
25, 26, 27, 28, 29, about 30 nucleotides or more.
In some embodiments, the miRNA interferes oncogenic
miRNA to regress cancer growth. The RNA nanostructure
molecule contains anti-miRNA that silences oncogenic miRNAs, including but not limited to, miR-9, miR-l0b, miR-21,
miR-17, and miR-26. In some embodiments, the miRNA

rescues down-regulated cancer suppressive miRNAs, where
the RNA nanostructure introduces cancer suppressive miRNAs, including but not limited to, let-7a, miR-l0b, miR-25,
miR-34a, miR-124, miR-145, and miR-181b. Further
examples is disclosed in US20140045709, which herein
incorporate by reference in its entirety.
The presently disclosed subject matter further provide a
composition including a therapeutically effective amount of
the RNA nanostructure molecule as disclosed above and
herein. In some embodiments, the composition further
includes a pharmaceutically acceptable carrier.
The presently disclosed subject matter in some embodiments provides a nanoparticle delivery system including a
RNA nano structure molecule as disclosed above and herein.
In some embodiments, the delivery system further includes
a pharmaceutically acceptable carrier.
The term "pharmaceutically acceptable carrier" as used
herein refers to a diluent, adjuvant, excipient, or vehicle with
which a heterodimeric probe of the disclosure is administered and which is approved by a regulatory agency of the
federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use
in animals, and more particularly in humans. Such pharmaceutical carriers can be liquids, such as water and oils,
including those of petroleum, animal, vegetable, or synthetic
origin, such as peanut oil, soybean oil, mineral oil, sesame
oil, and the like. The pharmaceutical carriers can be saline,
gum acacia, gelatin, starch paste, talc, keratin, colloidal
silica, urea, and the like. When administered to a patient, the
heterodimeric probe and pharmaceutically acceptable carriers can be sterile. Water is a useful carrier when the
heterodimeric probe is administered intravenously. Saline
solutions and aqueous dextrose and glycerol solutions can
also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical carriers also include
excipients such as glucose, lactose, sucrose, glycerol monostearate, sodium chloride, glycerol, propylene, glycol, water,
ethanol, and the like. The present compositions, if desired,
can also contain minor amounts of wetting or emulsifying
agents, or pH buffering agents. The present compositions
advantageously may take the form of solutions, emulsion,
sustained release formulations, or any other form suitable for
use.
The term "therapeutically effective amount," as used
herein, refers to the amount of a composition containing
administered to a patient already suffering from a disease,
condition, or disorder, sufficient to cure or at least partially
arrest, or relieve to some extent one or more of the symptoms of the disease, disorder, or condition being treated. The
effectiveness of such compositions depend upon conditions
including, but not limited to, the severity and course of the
disease, disorder, or condition, previous therapy, the
patient's health status and response to the drugs, and the
judgment of the treating physician. By way of example only,
therapeutically effective amounts may be determined by
routine experimentation, including but not limited to a dose
escalation clinical trial.
The specific therapeutically effective dose level for any
particular patient will depend upon a variety of factors
including the disorder being treated and the severity of the
disorder; the specific composition employed; the age, body
weight, general health, sex and diet of the patient; the time
of administration; the route of administration; the rate of
excretion of the specific compound employed; the duration
of the treatment; drugs used in combination or coincidental
with the specific compound employed and like factors well
known in the medical arts. For example, it is well within the
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skill of the art to start doses of a compound at levels lower
than those required to achieve the desired therapeutic effect
and to gradually increase the dosage until the desired effect
is achieved. If desired, the effective daily dose can be
divided into multiple doses for purposes of administration.
Consequently, single dose compositions can contain such
amounts or submultiples thereof to make up the daily dose.
The dosage can be adjusted by the individual physician in
the event of any contraindications. Dosage can vary, and can
be administered in one or more dose administrations daily,
for one or several days. Guidance can be found in the
literature for appropriate dosages for given classes of pharmaceutical products. In further various aspects, a preparation can be administered in a "prophylactically effective
amount"; that is, an amount effective for prevention of a
disease or condition.
Suitable methods for administering to a subject an effective amount of the composition in accordance with the
methods of the present disclosure include but are not limited
to systemic administration, parenteral administration (ineluding intravascular, intramuscular, intraarterial administration), oral delivery, buccal delivery, subcutaneous administration, inhalation, intratracheal installation, surgical
implantation, transdermal delivery, local injection, and
hyper-velocity injection/bombardment. Where applicable,
continuous infusion can enhance drug accumulation at a
target site (see, e.g., U.S. Pat. No. 6,180,082).
In some embodiments, the present disclosure provides a
method of treating gastric cancer in a subject having or at
risk of having gastric cancer. The method includes the step
of administering to the subject a therapeutically effective
amount of a composition comprising the RNA nanostructure
molecule as disclosed above and herein. In some embodiments, the method includes a composition further including
a pharmaceutically acceptable carrier. In some embodiments, the subject is a manimal or a non-mammal vertebrate.
In some embodiments, the subject is a human. More specifically, in the method, the RNA nanostructure molecule
includes a multiple branched RNA junction motif comprising at least one RNA oligonucleotides, and a gastric cancer
targeting module conjugated to the RNA junction motif. In
some embodiments of the method, the RNA nanostructure
further includes at least one bioactive agent. The RNA
nanostructure binds to gastric cancer cells. A non-limiting
example of the bioactive agent is a therapeutic agent. The
bioactive agent includes drugs, fluorescent dyes, or chemicals. In some embodiments, the bioactive agent includes an
imaging module. In some embodiment of the method, the
diameter of the RNA molecule is at least about 40 nm or less,
the molecule has zeta potential ranging from about -150 m V
to about 150 mV, and the molecule is substantially stable in
a pH value ranges from about 2 to about 13. In some
embodiments of the method, the nano structure comprises at
least one chemical modification at 2' position. Non-limiting
examples of the chemical modification includes 2'Fluoro,
2'Amine, and 2'O-Methyl. In some embodiments, the multiple branched RNA comprises sequence 5'-CCACAUAAAGGGCCCACUAuuCCCACAUACUUUGUUGAUCC-3' (SEQ ID NO: 4). In some embodiments,
the multiple branched RNA includes sequence
5'-UAGUGGGCCCUUUAUGUGG-3' (SEQ ID NO: 5). In
further embodiments, the multiple branched RNA junction
motif is a three-branched RNA junction motif. In some
embodiments of the present disclosure, the RNA molecules
form dimers, trimers, hexamers, and patterned superstructures. Further, In some embodiments, a branch of the threebranched RNA junction motif includes an a3WJ RNA

module (SEQ ID NO: 1); a b3WJ RNA module (SEQ ID
NO: 2); or a c3WJ RNA module (SEQ ID NO: 3). In one
embodiment, the three-branched RNA junction motif comprises an a3WJ RNA module (SEQ ID NO: 1); a b3WJ RNA
module (SEQ ID NO: 2); and a c3WJ RNA module (SEQ ID
NO: 3). The SEQ ID NO: 1 includes nucleotide sequence
5'-UUG CCA UGU GUA UGU GGG-3', the SEQ ID NO: 2
comprises nucleotide sequence 5'-CCC ACA UAC UUU
GUU GAUCC-3', and the SEQ ID NO: 3 comprises nucleotide sequence 5'-GGA UCA AUC AUG GCA A-3'.
Further, the gastric cancer targeting module includes a
ligand that binds to at least one gastric cancer cell surface
marker. In some embodiments, the ligand binds to a folate
receptor, an epidermal growth factor receptor 2 (ErbB-2/
HER2), an epidermal growth factor receptor (EGFR), a
HER2 or a combination thereof. In some embodiments, the
ligand is an aptamer. Non-limiting examples of the aptamer
are aptamers binding to EGFR, PDGFR, folate receptor, or
a combination thereof. In one example, the ligand is a EGFR
targeting aptamer. In one example, the ligand has sequence
5'-G CCU UAG UAA CGU GCU UUG AUG UCG AUU
CGA CAG GAG GC-3' (SEQ ID NO: 6). In some embodiments, the targeting module is a folate. Non-limiting
examples of folate are folic acid, 5-methyltetrahydro folate,
5-formyltetrahydrofolate, dihydrofolate, tetrahydrofolate, or
a combination thereof.
The RNA nano structure of the method further includes at
least one bioactive agent. The bioactive agent is a drug, a
fluorescent dye, a chemical, or a combination thereof. Further, the bioactive agent includes a siRNA, a miRNA, an
anti-mRNA, a ribozyme RNAs, or an antisense RNAs. In
some embodiments, the bioactive agent is directed a gastric
cancer marker. In some embodiments, the bioactive agent is
a siRNA sequence. Non-limiting examples of the siRNAare
siRNA is directed to Survivin, Bcl-2, XIAP, BCL-XL, or
BRCAAl. Non-limiting examples of the siRNA include
siRNA sequence 5' GGACCACCGCAUCUCUACAdTdT
3' (SEQ ID NO: 7), 5' dTdTCCUGGUGGCGUAGAGAUGU 3' (SEQ ID NO: 8), 5'-AAGCUGuCACAGAGGGGCUAC-3' (SEQ ID NO: 9), 5'GUAGCCCCUCUGUGACAGCUU-3
(SEQ
ID
NO:
10),
5'-CCAUGUGCUAUACAGUCAUUACUUU-3' (SEQ ID
NO: 11 ), 5'-AAAGUAAUGACUGUAUAGCACAUGG-3'
(SEQ ID NO: 12), 5'-UUGGACAAUGGACUGGUUGA-3'
(SEQ ID NO: 13), or 5'-UCAACCAGUCCAUUGUCCAA-3 (SEQ ID NO: 14). In one embodiment, siRNA is a
BRCAAl siRNA. A non-limiting example is a siRNA
sequence 5'-CCACAUAAAGGGCCCACUA-3' (SEQ ID
NO: 15). Another non-limiting example is a siRNA
sequence 5'-UAGUGGGCCCUUUAUGUGG-3' (SEQ ID
NO: 5). In some embodiments, the bioactive agent is a
microRNA sequence. In some embodiments, the bioactive
agent is an anti-miRNA molecule for a miRNA comprising
miR-9, miR-l0b, miR-21, or miR-26. In some embodiments, the bioactive agent is a miRNA molecule for a
miRNA comprising let-7a, miR-l0b, miR-25, miR-34a,
miR-124, miR-145, or miR-181b.
As used herein, the term "subject" refers to a target of
administration of the pharmaceutical composition. The subject of the herein disclosed methods can be a vertebrate, such
as a mammal, a fish, a bird, a reptile, or an amphibian. Thus,
the subject of the herein disclosed methods can be a human
or non-human. Thus, veterinary therapeutic uses are provided in accordance with the presently disclosed subject
matter. As such, the presently disclosed subject matter
provides for administration to mammals such as humans and
non-human primates, as well as those mammals of impor-
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tance due to being endangered, such as Siberian tigers; of
effect, improve the therapeutic effect, and exhibit great
economic importance, such as animals raised on farms for
potential in clinical tumor therapy.
consumption by humans; and/or animals of social imporMaterials and Methods
tance to humans, such as animals kept as pets or in zoos.
Construction and Characterization of FA Conjugated
Examples of such animals include but are not limited to: 5
BRCAAl-siRNA pRNA-3WJ nNnoparticles
carnivores such as cats and dogs; swine, including pigs,
The pRNA-3WJ nanoparticle consisted of three fraghogs, and wild boars; ruminants and/or ungulates such as
ments, a 3 wJ, b 3 wJ and c 3 wJ, was functionalized with folate,
cattle, oxen, sheep, giraffes, deer, goats, bison, and camels;
as targeting ligand; Alexa 647 , as imaging module; and
rabbits, guinea pigs, and rodents. Also provided is the
10 BRCAAl siRNA (or scrambled control), as therapeutic
treatment of birds, including the treatment of those kinds of
module. The RNA fragments were then synthesized chemibirds that are endangered and/or kept in zoos, as well as
cally (TriLink), self-assembled into RNAnanoparticles, and
fowl, and more particularly domesticated fowl, i.e., poultry,
characterized by 1.2% agarose gel shift assays and AFM
such as turkeys, chickens, ducks, geese, guinea fowl, and the
like, as they are also of economic importance to humans. 15 imaging as well as Zeta potential/Particle Sizer, as described
previously (52). The construct contains sequences as folThus, also provided is the treatment of livestock, including,
lowing:
but not limited to, domesticated swine, ruminants, ungulates, horses (including race horses), poultry, and the like.
The term does not denote a particular age or sex.
Strand 1,
(SEQ ID NO, 1)
Further, in some embodiments, the RNA nanoparticle 20
5' (folate)UUGCCAUGUGUAUGUGGG 3';
based nano-delivery platform is expected to outperform
treatment strategies for gastric cancer therapy in several
Strand 2,
aspects: (1) RNA nanoparticles have defined size, structure
(SEQ ID NO, 4)
5' CCACAUAAAGGGCCCACUAuuCCCACAUACUUUGUUGAUCC 3'
and stoichiometry. Unpredictable side effects arising from
heterogeneous particles can thus be avoided. (2) Nanoscaled 25 Strand 3,
size of the RNA nanoparticles facilitates tissue penetration
(SEQ ID NO, 3)
5' (Alexa 647)GGAUCAAUCAUGGCAA 3'
and target to tumor. (3) RNA nanoparticles are easy to
construct by self-assembly, highly soluble and not prone to
Strand 4,
aggregation. (4) The RNA nanoparticles are thermodynami(SEQ ID NO, 16)
30
cally stable and, therefore, the entire construct will remain
5' UAGUGGGCCCUUUAUGUGGuu 3'
intact at ultra-low concentrations in the body. (5) The
polyvalent nature of the RNA nanoparticle allows for easy
In order to evaluate the effects of a wide pH range on the
integration of targeting modules, imaging modules and
stability of RNA nanoparticles, the prepared RNA nanopartherapeutic modules into a single form. (6) RNA nanoparticles were dispersed in varied pH buffers for 12 h, RNA
ticles display low or no immunogenicity and/or toxicity even 35 nanoparticles/buffer=l:l(v/v), and pH ranged from 2 to 13
at high doses. The 3WJ-pRNA scaffold displays favorable
(Table 1: details of preparation of a series of buffer solupharmacokinetic and pharmacodynamic profiles in vivo
tions), then 1.2% agarose gel electrophoresis was used to
(half-life of 5-10 hours compared to 0.25-0.75 hours of the
characterize the stability of prepared RNA nanoparticles.
most stable 2'F modified siRNA counterparts); non-toxic;
Effects of pH on the fluorescent intensity of RNA nanoparand no induction of interferon or cytokines.
4o ticles were investigated by measuring the fluorescent intenThe presently disclosed subject matter is further illussity of RNA samples with different pH via the photolumitrated by the following specific but non-limiting examples.
nescence
(PL)
spectra
(Perkin
Elmer
LS55
The following examples may include compilations of data
spectrofluorimeter).
that are representative of data gathered at various times
during the course of development and experimentation 45
TABLE 1
related to the present disclosure.
Preparation for a series of buffer solutions (pH 2 to 13)

EXAMPLES
pH

This study reports the use of the thermostable three-way
junction (3WJ) of bacteriophage phi29 motor pRNA to
escort folic acid, a NIR image marker and BRCAAl siRNA
for targeting, imaging, delivery, gene silencing and regression of gastric cancer in animal models. In vitro assay
revealed that the RNA nanoparticles specifically bind to
gastric cancer cells, and knock-down the BRCAAl gene.
Apoptosis of gastric cancer cells was observed. Animal trials
confirmed that these RNA nanoparticles could be used to
image gastric cancer in vivo, while showing little accumulation in crucial organs and tissues. The volume of gastric
tumors noticeably decreased during the course of treatment.
No damage to important organs by RNA nanoparticles was
detectible. All the results indicated that this novel RNA
nanotechnology can overcome conventional cancer therapeutic limitations and opens new opportunities for specific
delivery of therapeutics to stomach cancer without damaging normal cells and tissues, reduce the toxicity and side

0.2M glycine (ml)

0.2M HCl (ml)

Deionized
water (ml)

4.4
1.14

10.6
13.86

50
2*
3*

55

4"
5"
6"
7"
8"

60
9-"
10"'

5
5
0.2M Na2 HPO4 (ml)

0.lM Citrate (ml)

7.71
10.3
12.63
16.47
19.15

12.29
9.7
7.37
3.53
0.85

0.2M glycine

0.2M NaOH

5
5
0.lM Na2 COs(ml)

65 11*

19

0.88
3.2
0.lM NaHCOs(ml)

14.12
11.8
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TABLE I-continued

subsequent BRCAAl gene silencing effects: one harboring
folate and BRCAAl siRNA; and, the other harboring folate
and BRCAAl siRNA scramble control. After 48 h of treatment, total RNAs from MGC803 cells were isolated by
using Trizol (Invitrogen) and Direct-zol™ RNA MiniPrep
(Zymo Research) according to manufacturer's instructions.
First-strand cDNA was obtained by using 1 µg of total RNA
and random primers and M-MLV reverse transcriptase (Promega ). All reactions were carried out in a final volume of 25
µI and assayed in triplicate. qRT-PCR was performed using
a BioRad iQ5 iCycler Detection System with a three-step
PCR protocol (95° C. for 10 min, followed by 40 cycles of
95° C. for 5 s, 60° C. for 30 s and 72° C. for 30 s) with
HieflTM qPCR SYBR® Green Master Mix (Yeasen). The
data was analyzed by the llllCT method. The primers for
BRCAAl and GAPDH are as follows:

Preparation for a series of buffer solutions (pH 2 to 13)
0.05M Na2 HPO4 (ml)

0.lM NaOH (ml)

10

5.38

0.2M KC!

0.2MNaOH

5
12*

13.2

4.62

1.8
10

*Glycine HCI buffer
A.Phosphate Citrate buffer
.&.Glycine NaOH buffer

*Crabonate Bicarbonate buffer
*Phosphate NaOH buffer
•Kcl NaOH buffer

The RNAnanoparticles contained 2'-F modified U and C
nucleotides to make them resistant to RNase degradation.
However, Effects of RNAase A on the stability of RNA
nanoparticles was still investigated. RNase A-free purified
water was used to dilute RNAse A (Sigma Company), the
resulting solutions were respectively exhibited different concentration of RNAse A (10 U, 50 U, 100 U, 500 U, 1000 U,
10000 U), then, each tube was respectively added into 1 µg
RNA nanoparticles, incubated at 37° C. for 12 h, then 10%
SDS-PAGE (sodium dodecylsulfate-polyacrylamide gel
electrophoresis) gel electrophoresis is used to observe
effects of RNAse A on the stability of RNA nanoparticles.
The pRNA-3WJ was prepared by diluting 100 µM of the
complexes in diethylpyrocarbonate (DEPC) treated water
with PBS at 1: 1 (v/v) right before the experiments.
Effects of Prepared RNA Nanoparticles on Cell Binding
Efficiency and Specificity
The human gastric cancer MGC803 cells and human
gastric epithelial GES-1 cells (Cell Bank of Type Culture
Collection of Chinese Academy of Sciences) were maintained at 37° C. (5% CO 2 ) in Dulbecco's Modified Eagle's
Medium (DMEM, HyC!one) supplemented with 10% (v/v)
fetal bovine serum (Gibco), 100 U/mL penicillin, and 1
mg/mL streptomycin. Cell culture products and reagents
were purchased from GIBCO. 200 nM AlexaF!uor647
labeled 3WJ-FA-A647 was incubated with lxl05 MGC803
and GES-1 cells at 37° C. for 1 h, after washing with PBS
for three times, the cells were collected and resuspended in
PBS buffer, followed by analyzed with a FACS Calibur (BD
Biosciences).
In order to investigate the specificity of RNA nanoparticles binding to MGC803 cells, MGC 803 cells were
cultured in a humidified 5% CO2 balanced air incubator at
37° C. for 2 days. All the cells were collected and implanted
onto 18 mm glass coverslips in a 12-well tissue culture plate,
and culturing was continued for 3 days. After the cells were
rinsed 3 times, 500 µL of medium containing prepared RNA
nanoparticles was added into each dish and incubated for 30
min. Three dishes of all dishes were first incubated with free
folic acids for 30 min, then incubated with RNA nanoparticles, then washed with PBS buffer, and then examined
under the dark field microscopy. Dark-field images were
obtained on an upright Olympus IX71 optical mi8croscope
integrated with a CRi Nuance multispectral imaging system
(Cambridge Research & Instrumentation, Inc., Woburn,
Mass., USA).
Effects ofRNANanoparticles on the Silencing ofBRCAAl
Gene in MGC803 Cells
MGC803 cells were transfected with a positive BRCAAl
siRNA control using Lipofectamine 2000 (Invitrogen) as the
carrier. Two 3WJ-RNA constructs were assayed for the
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BRCAAl,
forward:
( SEQ ID NO,

1 7)

(SEQ ID NO,

18)

(SEQ ID NO,

19)

(SEQ ID NO,

20)

5'-ACCAAATCTCCCGCAAGG-3';
reverse:

25

5'-CATATTTTCCAGGTCCGACA-3'.
GAPDH,
forward:
5'-GAAGGTGAAGGTCGGAGTC-3';
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reverse:

5'-GAAGATGGTGATGGGATTTC--3'.
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The qRT-PCR data were treated by using comparative Ct
method, the calculation formation is as follows: 2-llllCt;
llllCt=(treated group Ct-treated group GAPDH Ct)-(control
group Ct-control group GAPDH Ct). The results obtained
indicate the relative ratio is calculated that target gene
mRNA expression levels in the treated group are divided by
mRNA expression level in the control group.
For western blot assays, the total cell lysates were prepared in high KC! lysis buffer (10 mMTris-HCI, pH 8.0, 140
mM NaCl, 300 mM KC!, 1 mM EDTA, 0.5% Triton X-100
and 0.5% sodium deoxycholate) with complete protease
inhibitor cocktail (Roche). Thirty micrograms of protein
were separated by SDS-PAGE and electrophoretically transferred to PVDF membranes (Millopore). The membranes
were incubated respectively with BRCAAl antibody
(1:2000 diluted), Bcl-2 antibody (1:2000 diluted), Rb antibody (1:2000 diluted), Bax (1:2000 diluted) and ~-actin
antibody (Epitomics) (1:4000 diluted) for overnight, followed by 1:10000 anti-mouse secondary antibody conjugated with HRP (Epitomics) for 2 h. Membranes were
blotted by Westar EtaC ECL kits (Cyanagen Sri) and
exposed to film for autoradiography.
Effects of RNA Nanoparticles on Growth and Apoptosis of
MGC803 Cells
Effects of prepared RNA nanoprobes on viability of
MGC803 cells and GES-1 cells were analyzed using Cell
Counting Kit-8 (CCK8) assay (23). MGC803 cells and
GES-1 cells were cultured in the 96-well microplate at the
concentration of 5000 cells per well and incubated in a
humidified 5% CO2 balanced air incubator at 37° C. for 24
h. Except for control wells, the remaining wells were added
into medium with prepared RNA nanoparticles, final concentrations were, respectively, 10, 20, 40 and 80 µg/ml, then
those cells were continued to culture for 24 h, 48 h and 72
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h, respectively, then, the ODs were measured using the
thermomultiskan MK3 ELISA plate reader according to the
protocol of CCK8 assay kit, and calculated the survival rate
of cells. The survival rate of cells can be calculated by the
following equation:

by hematoxylin and eosin (HE) stain method, and were
observed by microscopy to confirm whether there is pathological lesion in important organs existed.
Statistical Analysis
Each experiment was repeated three times in duplicate.
The results were presented as mean±SD. Statistical differences were evaluated using the t-test and considered significance at P<0.05.
Results
Construction and Characterization of Triple-Functional
pRNA-3WJ Nanoparticles
The pRNA-3WJ nanoparticles were prepared by mixing
the three strands a3 wJ, b 3 wJ, and c 3 wJ respectively, at equal
molar ratio (FIG. la). Atomic force microscopy (AFM)
image highly suggested the formation of homogeneous
triangular branched architectures, confirming that pRNA3WJ nanoparticles were successfully prepared (FIG. lb).
Regarding the RNA nanoparticles' size and surface charge,
the dynamic light scattering experiments showed that the
size of the nanoparticle is 5.20±0.83 nm in diameter, and the
zeta potential is -16.57±0.75 my, as shown in FIGS. 12A
and 12B.
In order to evaluate the effects of a wide pH range on the
stability of RNA nanoparticles, the prepared RNA nanoparticles were dispersed in varied pH buffers (RNA nanoparticles/buffer= 1: l(v/v)) for 12 h. The details of the preparation of a series of buffer solutions with pH 2 to 13 were
shown in Table 1. The effects of pH on the fluorescent
intensity of RNA nanoparticles is investigated. As shown in
FIG. 13A, in the range of pH 2 to 13, RNA nanoparticles
exhibited different fluorescent intensity, and in the range of
pH 5-9, RNA nanoparticles displayed more than 90% strong
fluorescent signals. The study used 1.2% agarose gel electrophoresis to characterize the stability of prepared RNA
nanoparticles. As shown in FIG. 13B, tested RNA nanoparticles displayed identical position and similar brightness on
the gel, no degradation, suggesting that the RNA nanoparticles are stable in the range of pH 2 to 13.
The melting temperature of the 3WJ-BRCAA1 siRNA
nanoparticle was determined as 69.2±0.9° C. by real-time
PCR, as shown in FIG. 14. Melting experiments were
conducted by monitoring the fluorescence of the RNA
nanoparticles or the assembly intermediates using the LightCycler 480 Real-Time PCR System (Roche). lxSYBR
Green dye was used for all the experiments. The RNA
samples were dissolved in lxTMS buffer and slowly cooled
from 95 to 20° C. The melting temperature of the 3WJBRCAA1 siRNA nanoparticle was determined as 69.2±0.9°
C. The data represents the mean and standard deviation of
three independent experiments.
Effects of RNAase A on the stability of RNA nanoparticles were also investigated. RNase A-free purified water
was used to dilute RNAse A (Sigma Company). The resulting solutions were respectively exhibited different concentration of RNAse A (10 U, 50 U, 100 U, 500 U, 1000 U,
l0000U). Then each tube was respectively added l □ g RNA
nanoparticles, incubated at 37° C. for 12 h, and finally 10%
SDS-PAGE gel electrophoresis was used to examine the
effects of RNAse A on the stability of RNA nanoparticles. As
shown in FIG. 15, RNA nanoparticles on different lanes
exhibited identical position, similar brightness, no obvious
degradation, which highly suggests that prepared RNA
nanoparticles own good stability against RNase A (less than
10000 U) degradation.
The resultant pRNA-3WJ nanoparticles are thermodynamically and chemically stable, which makes them an
attractive candidate for in vivo nano-delivery for the purpose

5

Cell viability (%)~optical density(OD) oftbe treated
cells/OD of tbe non-treated cellsxl00

The prepared RNA nanoparticles were incubated with
MGC803 cells for 48 h, cell apoptosis and necrosis were
determined by Annexin V-FITC/PI double staining and
quantified by flow cytometry. Briefly, lxl0 5 MGC 803 cells
were harvested 48 h after transfection and resuspended in
100 µL binding buffer containing 5 µl annexin V-FITC and
5 µl PI provided with the Annexin V-FITC/PI Apoptosis
Detection Kit (Yeasen) for 15 min at room temperature in the
dark. Samples were then analyzed with a FACSCalibur (BD
Biosciences). The live cells were identified as Annexin
V-FITC-/PI- (lower left quadrant), early apoptotic cells as
Annexin V-FITC+/pI- (upper left quadrant), late-stage apoptotic cells as Annexin V-FITC+/pI- (upper right quadrant),
and necrotic cells as Annexin V-FITC-/PI+ (upper left quadrant). Annexin V-FITC/PI Apoptosis Detection Kit was
purchased from Yeasen Corporation (Shanghai, China).
RNA Nanoparticles for NIR Fluorescent Imaging ofln Vivo
Gastric Cancer
Female athymic nude mice (18-22 g) were purchased
from Shanghai Slac Laboratoty Animal Co. Ltd (Shanghai,
China). For the establishment of tumor model, MGC803
cells were resuspended in PBS and 2xl0 6 cells/site was
subcutaneously injected in the right flank. When the tumor
nodules had reached a volume of 0.1-0.3 cm3 after approximately 3 weeks post-injection, mice were used for biodistribution and imaging studies. For tumor imaging, FA-Alexa
Fluor 647-labeled pRNA-3WJ nanoparticle (about 20 nmol
in PBS buffer, equal 32 mg/kg) was administrated intravenously into the MGC-803-tumour-bearing mice. Timecourse fluorescent images (excitation: 630/20 nm, emission:
700/30 nm, integration time: 15 s) were acquired on a
Bruker In-Vivo F PRO imaging system (Billerica, Mass.).
All the post injection images were captured at the same
parameter setting and are scaled to the same maximum
values. For the ex vivo imaging, the mice (3 mice per time
point) were then sacrificed and collected tumors and the
major organs after 3, 24,48, 96 h and 7 day intravenously
(iv) injection. Excised tumor and organs were imaged by the
Bruker In-Vivo F PRO imaging system with the same
parameters as mentioned above.
RNA Nanoparticles for Targeted Therapy of In Vivo Gastric
Cancer
Nude mice loaded with gastric cancer MGC803 cells were
prepared according to the previous reports (12-15), and were
randomly divided into three groups: test group (10 mice)
(FA-pRNA-3WJ-BRCAAlsiRNA, 1 mg/kg body weight);
control group (10 mice) (FA-pRNA-3WJ-Scram siRNA, 1
mg/kg body weight) and blank control (10 mice) (untreated).
When the tumor sizes reached about 5 mm in diameter, the
nude mice were injected with prepared RNA nanoparticles
in PBS via tail vein (1 mg/kg body weight). Every two days,
the tumor volume was measured, up to 15 days. Then, these
mice were sacrificed.
Effects of RNA Nanoparticles on Important Organs
The mice in testing group were sacrificed after being
raised for 15 days. For histological evaluation, excised
important organs including heart, liver, spleen, lung and
kidney were frozen and embedded by medium at -20° C.,
and then were sectioned into 8 µm slices, then were stained
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of cancer detection or treatment. In this study, folate is
incorporated, as targeting ligand; Alexa 647 , as imaging module; and BRCAAl siRNA (or scrambled control) into the
pRNA-3WJ scaffold.
Binding Efficiency of pRNA Nanoparticles to Gastric Cancer Cell
Flow cytometry data in FIG. 2 showed that the prepared
3WJ-FA-A647 nanoparticles can bind with the MGC803
cells with almost 100% binding efficiency, while the GES-1
cells display a weak signal, which highly suggested that the
prepared RNA nanoparticles did not bind with GES-1 cells.
Results also demonstrate that folic acid receptor exhibits
over-expression on the surface ofMGC803 cells, no expression on the surface of GES-1 cells, similar to a previous
report (15).
Effects of RNA Nanoparticles on the Silence of BRCAAl
gene in MGC803 Cells
The qRT-PCR results in FIG. 3a showed that, prepared
FA-pRNA-3WJ-BRCAA1 siRNA nanoparticles could
silence expression ofBRCAAl gene in MGC803 cells after
incubating with MGC803 cells for 48 h, in contrast, prepared FA-pRNA-3WJ-Scram siRNAnanoparticles could not
silence expression ofBRCAAl gene in MGC803 cells after
incubation for 48 h, between two groups, there existed
statistical difference (P<0.01). Compared with BRCAAl
siRNA, prepared FA-pRNA-3WJ-BRCAA1 siRNA nanoparticles achieved similar silencing efficiency of BRCAAl
gene in MGC803 cells. The Ct, Delta Ct, and Delta Delta Ct
values for the qRT-PCR assay are shown in Table 2. Additionally, as shown in FIG. 3b, Western blotting results
further confirmed that prepared FA-pRNA-3WJ-BRCAA1
siRNA nanoparticles and BRCAAl siRNA could downregulate BRCAAl expression in MGC803 cells, while prepared FA-pRNA-3WJ-Scram siRNAnanoparticles had little
down-regulation of BRCAAl protein expression in
MGC803 cells, thus showing prepared FA-pRNA-3WJBRCAA1 siRNA nanoparticles can specifically silence
expression of BRCAAl protein in MGC803 cells. Importantly, the silencing potency was comparable to the Lipofectamine 2000 carried BRCAAl siRNA group.

Previous study shows that BRCAAl can inhibit MGC803
cell apoptosis and improve the proliferation of MGC803
cells, it is hypothesized that the performed RNA interference
(RNAi) by RNA nanoparticles could induce MGC803 cell
apoptosis. As shown in FIG. 5, the transfection with 25 nM
FA-pRNA-3WJ-BRCAA1 siRNAin MGC803 cells induced
2.51% of early apoptotic cells and 15.0% of late apoptotic
cells, respectively, in the normal control, MGC803 cells
exhibited 0.085% of early apoptotic cells, there existed
statistical difference between treated group with FA-pRNA3WJ-BRCAA1 siRNA and control group, P<0.05. The light
scattering plot of MGC 803 cells treated with FA-pRNA3WJ-BRCAA1 siRNA nanoparticles for 48 his shown in
FIG. 16. These results show that prepared FA-pRNA-3WJBRCAA1 siRNA nanoparticles can induce apoptosis of
MGC803 cells.
Fluorescent RNA Nanoparticles for In Vivo Imaging of
Gastric Cancer
It has been reported that unmodified siRNA ribonucleic
acid sequences have extremely poor pharmacokinetic properties due to short in vivo half-life and fast kidney clearance
caused by their small size (hydrodynamic diameters, HDs;
typically <5 nm, which is smaller than the kidney filtration
threshold (KFT) of 5.5 nm). Tumor targeting efficiency by
RNA nanoparticles was investigated by collecting and analyzing in situ fluorescence images of MGC803 xenografts in
nude mice at different post-injection (p.i.) time points (FIGS.
6a and c ). Tumor area was hardly distinguished in the mouse
in the first 30 min p.i. because of the strong fluorescence
background in normal tissues. However, as the time
increased, the decrease in the fluorescence background of
normal tissues and the accumulations at the tumor site
caused the tumor area became readily defined 5 h p.i. Ex
vivo images of normal tissues, organs, and tumors taken
from the RNA nanoparticles-injected mice showed that the
tumors taken at 5 and 24 h p.i. exhibited the strongest signal
(FIG. 6b). In terms of tumor accumulation kinetics, RNA
nanoparticles reached their highest accumulation within 5 h
and remained in the tumor site 96 h p.i., which indicted the
high tumor targeting efficiency and tumor retention capability of the constructed RNA nanoparticles.
RNA Nanoparticles for In Vivo Targeted Therapy of siRNA
to Gastric Cancer
As shown in FIGS. 7 and 8, the tumor in the mouse
without treatment grew very rapidly, the size of tumor
enlarged as a control. In contrast, the tumor in mice with
treatment showed regressed growth and the size of tumor is
smaller comparing to controls. The difference between
FA-pRNA-3WJ-BRCAAlsiRNA treated group
and
FA-pRNA-3WJ-Scram-siRNA treated group was statistically different (P<0.01). The result fully demonstrated that
prepared FA-pRNA-3WJ-BRCAA1 siRNA nanoparticles
can specifically inhibit the growth of gastric cancer cells in
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TABLE S2
The expression levels of BRCAAl normalized to the exogenous
GAPDH mRNA in the treated group and control group (the
Ct, Delta Ct, and Delta Delta Ct values).
group
GAPDH
BRCAAl-siRNA
FA-pRNA-3WJ-ScrambsiRNA
GAPDH
FA-pRNA-3WJBRCAAl-siRNA
GAPDH

45

LI.LI.Ct 2~veMCt P value

Ct

LI.Ct

6.943
14.931
20.566

7.988
13.623

1.435
4.427

0.485
0.051

0.005
0.001

6.944
15.194

8.252

1.507

0.404

0.000

50

6.942

Effects of RNA Nanoparticles on Growth and Apoptosis of
Gastric Cancer Cell MGC803
As shown in FIG. 4, MGC 803 cells were treated with 400
µg/mL FA-pRNA-3WJ-BRCAA1 siRNA nanoparticles for
24 h, 48 h and 72 h, the inhibition rate of MGC 803 cells
increased as the incubation time increased, at 48 h, maximal
inhibition rate of MGC803 cells is 44.5±2.6%, compared
with FA-pRNA-3WJ-Scram siRNA group, inhibition rate is
12.5±1.9%, there existed statistical difference between two
groups, P<0.01.
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Undetectable of Organ Damage by RNA Nanoparticles after
Systemic Injection.
Harris Hematoxylin and Eosin (HE) staining are used to
check the potential damage to important organs including
the heart, liver, spleen, lung and kidney by the RNA nanoparticles. As shown in FIG. 9, no obvious tissue damages
were observed, which indirectly suggested that the prepared
RNA nanoparticles displayed good biocompatibility and no
negative effects on important organs in the body was
observed.
In this study, in order to investigate the feasibility of
applying RNAnanoparticles as theranostic agents for gastric
cancer diagnosis and therapy, the pRNA-3WJ nanoparticle
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is designed consisting of three fragments, a3 wJ, b 3 wJ and
c 3 wJ, and functionalized with folate, as targeting ligand;
Alexa 647 , as imaging module; and BRCAAl siRNA (or
scrambled control), as therapeutic module, respectively.
FA-pRNA-3WJ-BRCAA1 siRNA nanoparticles is prepared
and the resulting RNA nanoparticles showed good pH and
thermodynamic stability, good stability against RNase A
(less than 10000 U) degradation, and exhibited stability of
fluorescent intensity. These results demonstrated that the
prepared RNA nanoparticles should be very stable in the
blood circulation and can act as high efficient theranostic
agent for targeted imaging and siRNA therapy of gastric
cancer in vivo, which lay foundation for RNAnanoparticles'
further clinical application.
Nanotoxicity of nanotheranostic agents has caused broad
attention. In this study, prepared RNA nanoparticles did not
exhibit obvious toxicity. After being injected into in vivo
blood circulation via tail vain, RNA nanoparticles gradually
accumulated in the site of in vivo tumor within 6 h p.i.,
clearly displayed the imaging of tumor tissues, and exhibited
specific targeting ability. The RNA nanoparticles were also
proved to be able to retention in the tumor for long time and
generate tumor regression effects.
In addition, the alteration of biochemical parameters in
the mice after treating with FA-pRNA-3WJ-BRCAA1
siRNA nanoparticles was investigated as shown in Table 3
and o obvious tissue damages were observed for liver and
kidneys. To study the effects ofRNAnanoparticles on blood
biochemical parameters, blood samples were centrifuged
twice at 3000 rpm for 10 min. Liver function was evaluated
with serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST). Nephrotoxicity was determined by blood urea nitrogen (BUN) and creatinine (Cr).
These parameters were all assayed using a Hitachi 7600
Automatic Biochemical Autoanalyzer.

In this study, the results of in vivo evaluation of therapeutic efficacy also showed that the prepared RNA nanoparticles can actively target in vivo gastric cancer tissues and
inhibited tumor growth significantly. However, the concrete
molecular mechanism is not well understood. In order to
investigate the potential molecular mechanism, Western
blotting is used to detect the expression level of BRCAAl,
Bcl-2, Rb and Bax in MGC803 cells treated with prepared
RNA nanoparticles for 24 hand 48 h. As shown in FIG. 10,
RNA nanoparticles can down-regulate or silence the expression of BRCAAl gene, down-regulate expression of Bcl-2
gene, adversely up-regulate expression of Rb and Bax genes
in MGC803 cells. Based on these results, a molecular
mechanism of RNA nanoparticle induced MGC803 growth
inhibition is studied: the prepared RNA nanoparticles (FApRNA-3WJ-BRCAA1 siRNA) actively bind to the folic acid
receptor on the surface of MGC803 cells via folic acids
conjugated on the RNA nanoparticles, and then induce the
endocytosis of RNA nanoparticles into tumor cytoplasm.
The double-stranded BRCAAl siRNA region on the RNA
nanoparticle can be recognized by RNA-induced silencing
complex (RISC) in the cytoplasm and processed. The
released siRNA antisense strand can further recognize target
BRCAAl mRNA, degrade it, and result in silence of
BRCAAl gene in MGC803 cells. The down regulate or
silencing of the BRCAAl gene will cause subsequent downregulation of Bcl-2 gene, and further up-regulation of Rb
and Bax gene, which will end up with inducing cell apoptosis and inhibiting the cell growth. The proposed mechanism is summarized in FIG. 11 and the concrete study of the
regulation signal pathway is under way.
In recent years, BRCAAl gene, as an important member
of ARID family, called as ARID4B, has been found to
involve in the regulation of the male fertility and stem cells,
ARID4B protein can regulate Rb binding protein 1, which
highly suggest that ARID4B may be a tumor suppressor.
Throughout this document, various references are mentioned. All such references are incorporated herein by reference, including the references set forth in the following
list.
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TABLE S3
Blood biochemical examination results
40
WBC

AST

ALT

Cr

UN

REFERENCES

FA-pRNA-3WJBRCAAl -siRNA NPs
20 µg
1 day
7 day
14 day
60 µg
1 day
7 day
14 day
FA-pRNA-3WJScramb-siRNA
20 µg
1 day
7 day
14 day
60 µg
1 day
7 day
14 day
Control
0

105

32

35

0.005

0.041

105
105
105

33
33
35

35
35
42

0.005
0.006
0.007

0.042
0.043
0.038

X

105
105

33
34

42
42

0.004
0.005

0.039
0.039

X

105

32

36

0.004

0.052

5

10
105
105

34
35
32

37
38
34

0.002

0.054

0.031

0.045

5

4.3

X

4.2
4.4
5.2

X

4.9
4.5

X

4.2
4.2
4.2
4.2

X
X

X
X
X

4.2
4.2

X
X

10
105

33
35

35
37

0.036
0.034

0.037
0.038

3.9

X

105

28

32

0.001

0.008

Further HE staining results also confirmed that prepared
RNA nanoparticles did not damage important organs such as
brain, heart, lungs, liver and kidneys. Therefore, it can be
confirmed that the prepared RNA nanoparticles should be
safe for in vivo application.
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SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS, 20
<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 1
LENGTH, 18
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 1
uugccaugug uauguggg

<210>
<211>
<212>
<213>
<220>
<223>

18

SEQ ID NO 2
LENGTH, 20
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 2
cccacauacu uuguugaucc

<210>
<211>
<212>
<213>
<220>
<223>

20

SEQ ID NO 3
LENGTH, 16
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 3
ggaucaauca uggcaa

<210> SEQ ID NO 4
<211> LENGTH, 41
<212> TYPE, RNA

16
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30
-continued

<213> ORGANISM, Artificial Sequence
<220> FEATURE,
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide
<400> SEQUENCE, 4
ccacauaaag ggcccacuau ucccacauac uuuguugauc c

<210>
<211>
<212>
<213>
<220>
<223>

41

SEQ ID NO 5
LENGTH, 19
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 5
uagugggccc uuuaugugg

<210>
<211>
<212>
<213>
<220>
<223>

19

SEQ ID NO 6
LENGTH, 39
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 6
gccuuaguaa cgugcuuuga ugucgauucg acaggaggc

39

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 7
LENGTH, 21
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide
<220> FEATURE,
<223> OTHER INFORMATION, Description of Combined DNA/RNA Molecule,
Synthetic oligonucleotide
<400> SEQUENCE, 7
ggaccaccgc aucucuacat t

21

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 8
LENGTH, 21
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide
<220> FEATURE,
<223> OTHER INFORMATION, Description of Combined DNA/RNA Molecule,
Synthetic oligonucleotide
<400> SEQUENCE, 8
ttccuggugg cguagagaug u

<210>
<211>
<212>
<213>
<220>
<223>

21

SEQ ID NO 9
LENGTH, 21
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 9
aagcugucac agaggggcua c

21
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32
-continued

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 10
LENGTH, 21
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 10
guagccccuc ugugacagcu u

<210>
<211>
<212>
<213>
<220>
<223>

21

SEQ ID NO 11
LENGTH, 25
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 11
ccaugugcua uacagucauu acuuu

<210>
<211>
<212>
<213>
<220>
<223>

25

SEQ ID NO 12
LENGTH, 25
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 12
aaaguaauga cuguauagca caugg

<210>
<211>
<212>
<213>
<220>
<223>

25

SEQ ID NO 13
LENGTH, 20
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 13
uuggacaaug gacugguuga

<210>
<211>
<212>
<213>
<220>
<223>

20

SEQ ID NO 14
LENGTH, 20
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 14
ucaaccaguc cauuguccaa

<210>
<211>
<212>
<213>
<220>
<223>

20

SEQ ID NO 15
LENGTH, 19
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 15
ccacauaaag ggcccacua

19
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33
-continued
<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 16
LENGTH, 21
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 16
uagugggccc uuuauguggu u

<210>
<211>
<212>
<213>
<220>
<223>

21

SEQ ID NO 17
LENGTH, 18
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 17
accaaatctc ccgcaagg

<210>
<211>
<212>
<213>
<220>
<223>

18

SEQ ID NO 18
LENGTH, 20
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 18
catattttcc aggtccgaca

20

<210> SEQ ID NO 19
<211> LENGTH, 19
<212> TYPE, DNA
<213> ORGANISM, Artificial Sequence
<220> FEATURE,
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 19
gaaggtgaag gtcggagtc

19

<210> SEQ ID NO 20
<211> LENGTH, 20
<212> TYPE, DNA
<213> ORGANISM, Artificial Sequence
<220> FEATURE,
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 20
gaagatggtg atgggatttc

20
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What is claimed is:
1. An artificial RNA nano structure molecule, comprising:
a multiple branched RNA junction motif comprising at least
one RNA oligonucleotide, and a gastric cancer targeting
module coupled to the RNA junction motif, wherein the
multiple branched RNA comprises sequence 5'
UAGUGGGCCCUUUAUGUGG 3' (SEQ ID NO: 5).
2. The molecule of claim 1, further comprising at least one
bioactive agent coupled to the RNA junction motif.
3. The molecule of claim 2, wherein the bioactive agent
comprises a an siRNA, an miRNA, an anti-mRNA, a
ribozyme RNAs, an antisense RNA, or a combination
thereof.
4. The molecule of claim 3, wherein the siRNA is directed
to Survivin, Bcl-2, XIAP, BCL-XL, or BRCAAl.
5. The molecule of claim 3, wherein the bioactive agent
comprises siRNA sequence 5' GGACCACCGCAUCUCUACAdTdT 3' (SEQ ID NO: 7), 5' dTdTCCUGGUGGCGUAGAGAUGU 3' (SEQ ID NO: 8), 5'-AAGCUGuCACAGAGGGGCUAC-3'
(SEQ
ID
NO:
9),
5'GUAGCCCCUCUGUGACAGCUU-3 (SEQ ID NO: 10),
5'-CCAUGUGCUAUACAGUCAUUACUUU-3' (SEQ ID
NO: 11 ), 5'-AAAGUAAUGACUGUAUAGCACAUGG-3'
(SEQ ID NO: 12), 5'-UUGGACAAUGGACUGGUUGA-3'
(SEQ ID NO: 13), 5'-UCAACCAGUCCAUUGUCCAA-3
(SEQ ID NO: 14), 5'-CCACAUAAAGGGCCCACUA-3'
(SEQ ID NO: 15), 5'-UAGUGGGCCCUUUAUGUGG-3'
(SEQ ID NO: 5).
6. The molecule of claim 3, wherein the bioactive agent
is an anti-miRNAmolecule for a miRNAcomprising miR-9,
miR-l0b, miR-21, or miR-26.
7. The molecule of claim 3, wherein the bioactive agent
is a miRNA molecule for a miRNA comprising let-7a,
miR-l0b, miR-25, miR-34a, miR-124, miR-145, or miR181b.
8. The molecule of claim 2, wherein the bioactive agent
comprises a drug, a fluorescent dye, a chemical, or a
combination thereof.
9. The molecule of claim 2, wherein the bioactive agent
is directed a gastric cancer marker.
10. The molecule of claim 1, wherein the nanostructure
comprises at least one chemical modification at 2' position,
wherein the chemical modification comprises 2' Fluoro, 2'
Amine, and 2' 0-Methyl.
11. The molecule of claim 1, wherein the multiple
branched RNA further comprises sequence 5' CCACAUAAAGGGCCCACUAuuCCCACAUACUUUGUUGAUCC 3' (SEQ ID NO: 4).

12. The molecule of claim 1, wherein the multiple
branched RNA junction motif is a three-branched RNA
junction motif.
13. The molecule of claim 12, wherein the three-branched
RNA junction motif comprises an a3 WJ RNA module (SEQ
ID NO: 1); a b3WJ RNA module (SEQ ID NO: 2); a c3WJ
RNA module (SEQ ID NO: 3), or any combination thereof.
14. The molecule of claim 1, wherein the diameter of the
molecule is at least about 40 nm or less.
15. The molecule of claim 1, wherein the molecule has
zeta potential ranging from about -150 m V to about 150 m V.
16. The molecule of claim 1, wherein the molecule is
substantially stable in a pH value ranges from about 2 to
about 13.
17. The molecule of claim 1, wherein the gastric cancer
targeting module comprises a ligand that binds to at least one
gastric cancer cell surface marker.
18. The molecule of claim 17, wherein the ligand binds to
a folate receptor, an epidermal growth factor receptor 2
(ErbB-2/HER2), an epidermal growth factor receptor
(EGFR), a HER2 or a combination thereof.
19. The molecule of claim 18, wherein the targeting
module is a folate.
20. The molecule of claim 17, wherein the ligand is an
aptamer.
21. The molecule of claim 20, wherein the aptamer binds
to EGFR, PDGFR, folate receptor, or a combination thereof.
22. The molecule of claim 21, wherein the ligand has
sequence 5'-G CCU UAG UAA CGU GCU UUG AUG
UCG AUU CGA CAG GAG GC-3' (SEQ ID NO: 6).
23. A composition comprising the artificial RNA nanostructure molecule of claim 1 and a pharmaceutically acceptable carrier.
24. A nanoparticle delivery system, comprising the artificial RNA nano structure of claim 1 and a pharmaceutically
acceptable carrier.
25. A method of treating gastric cancer in a subject having
gastric cancer, comprising administering to the subject a
therapeutically effective amount of a composition comprising the artificial RNA nanostructure of claim 1 and a
pharmaceutically acceptable carrier.
26. An artificial RNA nanostructure molecule, comprising: a multiple branched RNA junction motif comprising at
least one RNA oligonucleotide, and a gastric cancer targeting module coupled to the RNA junction motif, further
comprising at least one bioactive agent coupled to the RNA
junction motif, wherein the bioactive agent comprises
siRNA sequence 5'-UAGUGGGCCCUUUAUGUGG-3'
(SEQ ID NO: 5).
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